April 9, 2026
Enclomiphene and Fertility: Why Men Choose This Over TRT
Enclomiphene fertility discussions center on preserving spermatogenesis compared with exogenous testosterone. Here is trial language, not marketing: what randomized data showed in secondary hypogonadism, and what still requires clinician judgment.
The phrase “enclomiphene fertility” captures a prioritization conflict many men feel: treat symptoms now versus protect future fertility. Exogenous testosterone can suppress gonadotropins and reduce sperm production in many men—so telehealth narratives sometimes position enclomiphene as a middle path. The most defensible public statement is trial-specific: enclomiphene has been studied as an oral therapy intended to raise testosterone while avoiding the sperm suppression pattern observed with transdermal testosterone in a randomized comparison.
What Wiehle et al. (2014) reported in secondary hypogonadism
In a randomized phase II trial of men with secondary hypogonadism, enclomiphene citrate increased morning testosterone and increased LH compared with baseline patterns described in the publication, while sperm counts were conserved relative to the topical testosterone arm’s suppression signal (Wiehle et al., Fertil Steril, 2014; NCT01270841). Outcomes are population-level; individual fertility plans still need semen testing and specialist input.
Why men still choose TRT despite fertility tradeoffs
Some patients prioritize rapid symptom relief, predictable dosing, or prior success with testosterone formulations. Others have contraindications or poor tolerance to alternative pathways. Public articles cannot rank those private tradeoffs; they can only flag that fertility-aware planning should be explicit before starting exogenous testosterone when conception matters.
For contrast on categories, read enclomiphene versus TRT differences and bring the questions to a clinician who can interpret your labs and goals.